Hossein Borghaei, DO | Authors

Articles

Unmet Needs and Future Directions in Extensive-Stage SCLC

June 21, 2021

Hossein Borghaei, DO, shares insights regarding future directions and current unmet needs in extensive-stage small cell lung cancer. He provides advice to researchers about the importance of clinical trials in the setting of extensive-stage small cell lung cancer.

First-Line Treatment Recommendations for ES-SCLC

June 21, 2021

Hossein Borghaei, DO, reviews the currently accepted first-line treatment recommendation for extensive-stage small cell lung cancer: a triple combination of carboplatin, etoposide, and a checkpoint inhibitor (atezolizumab or durvalumab). He provides an overview of the IMpower and CASPIAN trials.

Case Overview: A 59-Year-Old Man With ES-SCLC

June 21, 2021

A thoracic oncologist, Hossein Borghaei, DO, provides an overview of the initial presentation, clinical work-up, treatment, and follow-up of a 59-year-old man with extensive-stage small cell lung cancer.